Description:

"Receptor associated proteins and precision neuromedicines"

Targeted therapy for neuropsychiatric disorders requires selective modulation of dysfunctional neuronal pathways. Receptors relevant to CNS disorders typically have associated proteins discretely expressed in specific neuronal pathways; these accessory proteins provide a new dimension for drug discovery. Recent studies show that targeting a TARP auxiliary subunit of AMPA receptors selectively modulates neuronal excitability in specific forebrain pathways relevant to epilepsy. Other medicinally important ion channels, gated by glutamate, g-aminobutyric acid (GABA), and acetylcholine, also have associated proteins, which may be druggable. This emerging pharmacology of receptor-associated proteins provides a new approach for improving drug efficacy while mitigating side effects.

Thursday October 26, 2023
CAN Seminar Series 
2:00 PM - 3:00 PM
Location: Ward 5-230 

David S. Bredt, M.D., Ph.D.
Chief Scientific Officer 
Founder of Rapport Therapeutics